Apixaban for the prevention of venous thromboembolism in people ...

Table 5.15 Base case results in THR (adapted from Table 95, MS-page 186)
Technologies
Total
costs (£)
Total QALYs
Comparison with conventional treatment
Incremental
costs (£)
(Enoxaparin)
Incremental
QALYs
54
ICER
(£/ QALY)
Apixaban 196.81 9.535 -238.98 0.015 Dominant
Comparator
Full incremental analysis
Incremental
costs (£)
Incremental
Rivaroxaban 226.28 9.536 -209.51 0.016 Dominant Apixaban 29.47 0.001 21,661
QALYs
ICER (£/
(QALY)
Dabigatran 263.89 9.523 -171.90 0.003 Dominant Rivaroxaban 37.61 -0.013 Dominated
Enoxaparin 435.79 9.520 Rivaroxaban 209.51 -0.016 Dominated
Abbreviations: ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years
Table 5.16 Base case results in TKR (adapted from Table 96, MS-page 186)
Technologies
Total
costs (£)
Total QALYs
Comparison with conventional treatment
Incremental
costs (£)
(Enoxaparin)
Incremental
QALYs
ICER
(£/ QALY)
Rivaroxaban 332.66 9.090 -301.51 0.068 Dominant
Comparator
Full incremental analysis
Incremental
costs (£)
Incremental
QALYs
ICER (£/
(QALY)
Apixaban 360.54 9.075 -273.63 0.052 Dominant Rivaroxaban 27.88 -0.015 Dominated
Dabigatran 514.80 9.028 -119.36 0.005 Dominant Rivaroxaban 182.15 -0.063 Dominated
Enoxaparin 634.17 9.023 Rivaroxaban 301.51 -0.068 Dominated
Abbreviations: ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years
Copyright 2011 Queen’s Printer and Controller of HMSO. All rights reserved.